February 22, 2011 ·
Leave a comment
Industry Insights from Paul Meade, M.Sc. MPH
With the Sunshine Act getting closer to implementation, every company that works with thought leaders is preparing for full disclosure and transparency in the way they work and compensate these physicians and other medical experts. So the big question at hand is this–just how many thought leaders should a healthcare manufacturer work with going forward? Some say just a few and others say many. What’s the right answer here?
If we take the argument that working with just a select few is better, one could surmise that it is best to cement a working relationship with a few key thought leaders rather than get to know a “cast of hundreds.” This way, companies may gain a better understanding of the respective key opinion leaders’ interests, preferences, beliefs, and skills. Companies can more effectively create a set of activities that most appropriately matches the skills and experiences of each physician and work with the strengths of each physician to bring new insights into new medical treatment options.
But the one factor working against the “less is more” option is the fact that many academic medical institutions are placing limits on how much remuneration a thought leader can accept from the industry in a given year. Whereas, not too long ago, managed care organizations were placing providers ... read more »
TAGS: 
biopharmaceutical industry capitation system compensation consultative services fees full disclosure health issues healthcare manufacturer industry insights key oopinion leaders KOL limits managed care organizations medical experts medical treatment options new insight patient advocacy gorups Paul Meade physicians product development remuneration specialists Sunshine Act thought leaders transparency Unique skills well-balanced
December 30, 2010 ·
Leave a comment
Prateek Peres-da-Silva, an intern at Thought Leader Select and student at the University of North Carolina’s Kenan-Flagler Business School, recently sat down with Dr. Maher “Max” Noureddine, Thought Leader Select’s departing chief scientific officer, to discuss his achievements at the company, as well as his vision for the non-profit he is launching to improve the professional lives of health care providers. Peres-da-Silva is a junior at UNC, double-majoring in business and biochemistry.
Prateek Peres-da-Silva: Good morning, Max. I’d like to hear some of your thoughts on your time at Thought Leader Select. Can you share a little about yourself and your role with the company?
Max Noureddine: Yes, Prateek. In terms of my training, I am a molecular geneticist with experience in biomedical research. I did my doctoral training in the genetics of cell cycle regulation, and then focused on the molecular genetics of neurodegenerative disorders as well as cancer. I joined Thought Leader Select in the fall of 2007 as the chief scientific officer and director of product development. In collaboration with an outstanding team at the company, I became responsible for the development and execution of the company’s line of competitive services and solutions in the area of key opinion leader assessments and profiling in particular, and in pharmaceutical consulting in general. As CSO, I am responsible for validating the ... read more »
TAGS: biomedical research biopharmaceutical biotechnology cancer cell cycle regulation health care providers impact mapping Kenan-Flagler Business School key opinion leaders KOL engagement KOL identification KOL profiling KOLs Maher Noureddine molecular genetics neurodegenerative disorders pharmaceutical Prateek Peres-da-Silva product development Thought Leader Index Thought Leader Select Thought Leader Select Innovation Lab UNC value mapping
June 16, 2010 ·
Leave a comment
Daniel Bagi joined Thought Leader Select to steer the company’s business development efforts in Latin America in the spring of 2010. With over two decades working for pharmaceutical and biotechnology companies, Dr. Bagi brings a high level of industry expertise to his consulting work with Thought Leader Select’s clients and prospects.
Daniel earned a Doctor of Medicine degree from the University of Monterrey (Mexico), and he has served the industry in a variety of capacities, including product development, regulatory affairs, licensing, and business development. He directed global clinical development for a suite of anti-cancer drug therapies at Lorus Therapeutics of Markham, Ontario and IGT Pharma of Vancouver, British Columbia.
More recently, Dr. Bagi has served as a senior consultant to EM Diagnostics, a US-based breast cancer diagnostic company, and, since 2005, he has served as a medical consultant to Riso Pharma Tech, a Toronto company dedicated to developing pharmaceuticals for Latin America and the Middle East.
TLS Blog: Good morning, Daniel. Please tell us why you decided to join us at Thought Leader Select.
Daniel Bagi: For me, one of the most important aspects of any professional endeavor is the work environment, which is defined by the attitudes and expertise of your colleagues. Negativity can cause failure. I was first approached by Neil Mellor (principal business development agent for North America), and Neil is ... read more »
TAGS: anti-cancer drug therapies biotechnology breast cancer business development Daniel Bagi Doctor of Medicine EM Diagnostics IGT Pharma investment banking key opinion leaders KOL engagement KOL identification KOL profiling KOLs Latin America liberal arts Lorus Therapeutics medical experts medical school Neil Mellor Paul Meade pharmaceutical pharmaceutical licensing product development regulatory affairs Riso Pharma Tech tennis Thought Leader Select thought leaders University of Monterrey University of Toronto
April 28, 2010 ·
Leave a comment
As the biopharmaceutical industry continues to pursue expansion in emerging markets, academic and practicing health care professionals will become more critical to a company’s success. Mexico, for example, is positioning itself as one of the most promising emerging markets according to Focus Reports. The sheer size of this market, combined with its lower healthcare spending, growing purchasing power, and changing biopharma industry make Mexico an attractive market for expansion.
To understand the changing landscape of government regulations—to universalize healthcare, develop regulatory standards, and protect innovative and generic drug patents— companies entering this market will need to identify and develop relationships with respected medical academics and community physicians.
Recognizing the immense growth potential of Mexican and Latin American markets for its biopharmaceutical clients, Thought Leader Select recently began offering KOL identification, profiling and deployment services in the region. With business development team members “on the ground” in Mexico and Latin America, Thought Leader Select is uniquely suited to assist multinational pharma corporations and local pharmaceutical companies in identifying KOLs at various levels (academic, community, etc.) and in understanding how to engage them during the development of new medicines that will positively impact public health.
Dr. Daniel Bagi, a 20-year veteran of the Latin American pharmaceutical industry, is leading Thought Leader Select’s efforts to bring innovative KOL identification, profiling, ... read more » TAGS: biotechnology key opinion leadrers KOL deployment KOL identification KOL management KOL profiling Latin America Mexico pharmaceutical product development Thought Leader Select
